The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

Bicycle modifications can potentially improve genitourinary outcomes after cycling. For example, in our cohort, cyclists who stood more than 20% of the time while cycling and adjusted the handlebar to ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

In this interview, Arpeet Shah, MD, considers some of the advancements and challenges that the field of urology will face in the coming year. Shah is a urologist at Associated Urological Specialists, ...

Key Takeaways Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed ...

The AUA released its guidelines in 2018, making a strong recommendation that clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate ...

In this episode of Speaking of Urology ®, Ashley G. Winter, MD, discusses the use of vaginal estrogen. Winter is a urologist and sexual medicine expert in Los Angeles, California. This discussion ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Using the PhalloFILL system, a novel hyaluronic acid filler, appeared to be safe when administered for penile girth enhancement, according to a retrospective review presented at the 24th Annual Fall ...

Key Takeaways Nadofaragene firadenovec achieved a 79% complete response rate in CIS patients at three months, with durable responses at six and nine months. Real-world safety data showed mostly ...